Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of the active pharmaceutical ingredient, Sitagliptin Phosphate, which is primarily used for improving blood sugar control in patients with type 2 diabetes [1] Company Summary - The company involved is Sinopharm Modern (国药现代), which is a subsidiary of Sinopharm Group [1] - The approved product, Sitagliptin Phosphate, is classified as a DPP-4 inhibitor [1] Industry Summary - Sitagliptin Phosphate is utilized in the clinical management of type 2 diabetes, indicating a focus on diabetes treatment within the pharmaceutical industry [1]

智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团威奇达药业有限公 司(简称国药威奇达)收到国家药品监督管理局关于原料药磷酸西格列汀的《化学原料药上市申请批准通 知书》。 磷酸西格列汀为DPP-4抑制剂，临床上主要用于改善2型糖尿病患者的血糖控制。本次国药威奇达的磷 酸西格列汀原料药获得《化学原料药上市申请批准通知书》，表明该原料药符合国内药品注册的有关规 定要求，可以在国内市场进行销售，将进一步丰富公司特色专科原料药产品群。 ...

Core Insights - The company Guoyao Modern has received approval for the listing application of the chemical raw material drug, phosphate sitagliptin, from the National Medical Products Administration [1] Company Summary - Guoyao Modern's wholly-owned subsidiary, Guoyao Weiqida, is responsible for the development of phosphate sitagliptin, which is a DPP-4 inhibitor primarily used for improving blood sugar control in patients with type 2 diabetes [1] - The total research and development investment for the phosphate sitagliptin raw material drug has reached approximately 5.29 million yuan [1]

Core Viewpoint - The announcement by China National Pharmaceutical Group Modern (国药现代) regarding the approval of the active pharmaceutical ingredient, phosphate sitagliptin, indicates a significant advancement in the company's product offerings in the diabetes treatment sector [1] Company Summary - China National Pharmaceutical Group Modern's wholly-owned subsidiary, China National Pharmaceutical Wichida, has received the approval notice from the National Medical Products Administration for the marketing application of phosphate sitagliptin [1] - Phosphate sitagliptin is classified as a DPP-4 inhibitor, primarily used in clinical settings to improve blood sugar control in patients with type 2 diabetes [1]

Core Viewpoint - The announcement from China National Pharmaceutical Group Modern (国药现代) regarding the resignation of Vice President Wei Dongsong due to job relocation indicates potential changes in the company's leadership structure and operational strategy [2] Group 1 - The company's board of directors received a written resignation application from Vice President Wei Dongsong [2] - Wei Dongsong is resigning from his position as Vice President and other roles in the company's subsidiaries [2] - The reason for the resignation is stated as a job relocation [2]

Group 1 - Changyuan Power reported a power generation of 2.742 billion kWh in September, a year-on-year decrease of 41.88% [1] - The cumulative power generation from January to September was 27.332 billion kWh, down 8.24% year-on-year [1] - Huanyu Electronics achieved a consolidated revenue of 5.96 billion yuan in September, a year-on-year increase of 0.1% [1][2] Group 2 - Zhonghuan Environmental announced a change in controlling shareholder, with 27.5% of shares being transferred for a total consideration of 598 million yuan [2] - *ST Songfa's subsidiary signed contracts for the construction of 6 VLCCs, with a total contract value of approximately 600-900 million USD [1][3] - Suzhou Xinchen Technology's subsidiary plans to acquire 55% of Kunyu Lancheng for 74.25 million yuan [3] Group 3 - Guiguan Power reported a cumulative power generation of 31.848 billion kWh for the first three quarters, a year-on-year increase of 14.89% [4] - Jincheng Pharmaceutical's subsidiary received approval for the market launch of a raw material drug [4] - Shandong Steel expects a net profit of approximately 140 million yuan for the first three quarters, an increase of about 21.96 million yuan year-on-year [4][5] Group 4 - Xiangjia Co. reported sales revenue of 96.6186 million yuan from live poultry in September, with a sales price of 12.10 yuan/kg [6] - Aonong Bio's pig sales volume in September increased by 12.2% year-on-year, with a total of 164,400 pigs sold [7] - Mingtai Aluminum's aluminum plate and foil sales reached 1.1747 million tons in the first three quarters [8] Group 5 - Guangzhou Port expects to complete a container throughput of 2.051 million TEUs in September, a year-on-year decrease of 0.8% [11] - Jiangsu Sop plans to conduct a month-long maintenance on several production units starting October 10 [12] - Baike Bio received approval for a clinical trial of a combined vaccine for infants [13] Group 6 - Yutong Bus reported a 25.55% year-on-year increase in bus sales in September, totaling 4,756 units [16] - Shanghai Rural Commercial Bank's vice chairman and president's qualifications were approved [19] - Huayu Pharmaceutical's product received market approval in four countries [20] Group 7 - Longan Automobile reported a 24.92% year-on-year increase in vehicle sales in September, totaling 266,300 units [38] - Chip Origin expects a third-quarter revenue of 1.284 billion yuan, a year-on-year increase of 78.77% [39] - Bomaike signed a contract for an offshore floating production storage and offloading vessel project, with a contract value of approximately 190-240 million USD [40]

上海现代制药股份有限公司 关于高级管理人员离任的公告 魏冬松先生在公司工作期间恪尽职守、勤勉尽责，公司及董事会对魏冬松先 生多年来为公司发展做出的贡献表示衷心感谢！ 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海现代制药股份有限公司（以下简称公司）董事会近日收到公司副总裁魏 冬松先生的书面辞职申请。魏冬松先生因工作调动，申请辞去公司副总裁及在公 司所属子公司兼任的其他职务，具体情况如下。 二、离任对公司的影响 根据《中华人民共和国公司法》和《公司章程》等相关规定，魏冬松先生的 辞职报告自送达公司董事会之日起生效。截至本公告披露日，魏冬松先生兼任公 司全资子公司上海现代制药营销有限公司董事、法定代表人，国药集团工业有限 公司董事，在上述两家公司完成相关人员变更之前，魏冬松先生将继续履行有关 法定职责。 魏冬松先生所负责的相关工作已完成交接，其离任不会影响公司正常的生产 经营。截至本公告披露日，魏冬松先生持有公司股票 20,000 股，其离任后将严 格遵守《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》及其 他有 ...

上海现代制药股份有限公司发布公告称，公司副总裁魏冬松因工作调动，于10月9日申请辞去副总裁及 在公司所属子公司兼任的其他职务，原定任期到11月28日。其辞职报告自送达董事会之日起生效，在相 关子公司完成人员变更前，他将继续履行法定职责。魏冬松负责的工作已完成交接，离任不会影响公司 正常经营。他持有公司股票20,000股，离任后将遵守股份买卖规定。 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-076 上海现代制药股份有限公司 关于全资子公司获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团容 生制药有限公司（以下简称国药容生）收到国家药品监督管理局核准签发的《药 品补充申请批准通知书》，批准维生素 B6注射液增加规格并通过仿制药质量和 疗效一致性评价（以下简称一致性评价），核发药品批准文号。现将相关情况公 告如下： 一、药品基本信息 药品名称：维生素 B6注射液 审批结论：根据《中华人民共和国药品管理法》《国务院关于改革药品医疗 器械审评审批制度的意见》（国发〔2015〕44 号）《关于仿制药质量和疗效一 致性评价工作有关事项的公告》（2017 年第 100 号）和《国家药监局关于开展 化学药品注射剂仿制药质量和疗效一致性评价工作的公告》（2020 年第 62 号） 的规定，经审查，批准本品增加 1ml:0.1g 规格的补充申请，核发药品批准文号， 本品通过 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-075 上海现代制药股份有限公司 第八届董事会第二十四次（临时）会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海现代制药股份有限公司（以下简称公司）第八届董事会第二十四次（临 时）会议，于 2025 年 9 月 22 日以通讯表决的方式召开。本次会议的通知和资料 已于 2025 年 9 月 16 日以电子邮件方式发出。本次会议应参会董事 8 名，实际参 会董事 8 名。会议的召集召开符合《公司法》和《公司章程》的有关规定，合法 有效。 二、董事会会议审议情况 本次会议审议并通过了如下事项： 表决结果：同意 8 票，反对 0 票，弃权 0 票。 同意增补蔡买松先生为公司第八届董事会战略与投资委员会委员，任期至本 届董事会届满时止。 3、审议通过了《2025 年度内控体系建设与监督评价工作方案》。 表决结果：同意 8 票，反对 0 票，弃权 0 票。 特此公告。 上海现代制药股份有限公司董事会 2025 年 9 月 23 日 ...